
LSTA Stock Forecast & Price Target
LSTA Analyst Ratings
Bulls say
Lisata Therapeutics Inc has shown promising progress in its clinical trials for certepetide, particularly highlighted by the positive preliminary data from Cohort A, which indicated an upward trend in overall survival and recorded four complete responses. The advancements in Cohort B suggest that a second dose of certepetide may enhance both progression-free survival (PFS) and overall response rate (ORR) for patients suffering from metastatic pancreatic ductal adenocarcinoma (mPDAC). These key clinical findings reinforce the company's dedication to developing effective therapies for solid tumors, potentially enhancing its value in the competitive pharmaceutical market.
Bears say
Lisata Therapeutics Inc. faces significant risks regarding its future performance primarily due to the uncertainty associated with its clinical trials, where failed or inconclusive results could severely hinder its progress. Additionally, the company may struggle to secure adequate funding necessary to advance its investigational drug, certepetide, through crucial stages of development. These challenges contribute to a negative outlook for the stock, as successful commercialization of its therapies is contingent upon overcoming these substantial hurdles.
This aggregate rating is based on analysts' research of Lisata Therapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.
LSTA Analyst Forecast & Price Prediction
Start investing in LSTA
Order type
Buy in
Order amount
Est. shares
0 shares